The CenterWatch Monthly, November 2012

Thursday, November 1, 2012 08:00 AM

Keeping potential patients connected to trials

Industry efforts to address patient recruitment challenges have widely overlooked an important issue: What happens to patients who volunteer to participate in a clinical trial but do not meet the eligibility criteria? How well does the industry do in helping them find other trial opportunities? When patients volunteer for a clinical trial but are disqualified during the screening process, for any number of reasons, many are disappointed and disillusioned, and give up on participation altogether. While in the past, the industry has not addressed this issue, recent initiatives have emerged that allow companies to share more information about trials actively enrolling and redirect volunteers who don’t qualify for one study into other studies. In one groundbreaking effort…

 

Sponsors, CROs demanding more from pre-study site visits

Under increasing pressure to shorten the drug development life cycle and boost efficiency, sponsors and CROs are demanding more from the pre-study site visit. They’re now more likely than in the past to use historical data and external sources of information to evaluate site potential before the visit. Once underway, the more sophisticated—and successful—site visits probe deeply into patient recruitment ability. For those sponsors and CROs that treat it as a proforma visit, or delegate the visit to a poorly trained or uninformed CRA, it can result in a missed opportunity and waste of resources...

 

Eye on BioMarin

BioMarin’s mission statement is “making a meaningful impact in the lives of patients suffering from diseases that are often underserved and ignored,” primarily by replacing deficient enzymes in rare genetic diseases. Currently the company is marketing four products: Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU) and Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome. Collaborations with research scientists and universities…

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs